ACM
MIST icon

Altium Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Altium Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-440,000
Closed -$669K – 80
2024
Q3 		$669K Sell
440,000
-572,368
-57% -$833K 0.2% 52
2024
Q2 		$1.34M Sell
1,012,368
-200,514
-17% -$322K 0.55% 31
2024
Q1 		$2.17M Buy
+1,212,882
New +$1.97M 0.86% 32

Other funds holding MIST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Altium Capital Management's MIST Position: Q4 2024 in Review

Altium Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q4 2024, closing a stake of 440,000 shares — an estimated $669K sold.

Altium Capital Management first reported a position in MIST in Q1 2024 and held it in 3 quarters. The position peaked at $2.17M in Q1 2024. 47 funds tracked by Wall St. Rank hold MIST as of Q4 2024.

  • Altium Capital Management reported no remaining Milestone Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Altium Capital Management sold 440,000 Milestone Pharmaceuticals shares in Q4 2024, an estimated $669K.
  • Altium Capital Management first reported a position in Milestone Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Altium Capital Management's Milestone Pharmaceuticals position peaked at $2.17M in Q1 2024.
  • 47 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.